Biotech and Medtech Companies Flood Stifel and Guggenheim Healthcare Conferences With Pipeline Updates

A wave of clinical-stage and commercial biotech and medtech companies presented at three simultaneous healthcare investor conferences during the week of November 10, 2026: the Stifel 2026 Healthcare Conference, the 3rd Annual Guggenheim Healthcare Innovation Conference, and the Canaccord Medtech Forum. The presentations spanned oncology, neurology, rare disease, medical devices, and AI-driven drug discovery, with several companies using the forums to announce specific pipeline milestones or strategic shifts.

The most concrete clinical news came from enGene Therapeutics, which reported updated efficacy data from Cohort 1 of its Phase 2 LEGEND trial of detalimogene voraplasmid in 125 patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. The company simultaneously announced plans to initiate a BLA submission for detalimogene by year end, marking a significant regulatory step for the non-viral genetic medicine. Argá Medtech also disclosed a clinical enrollment milestone, announcing the completion of enrollment of its paroxysmal atrial fibrillation cohort in the COHERENT-AF pivotal IDE study.

Across the Stifel conference, companies signaled near-term catalysts and strategic pivots. uniQure highlighted its gene therapy AMT-130 approaching a key readout, Tectonic Therapeutics pointed to a 2027 catalyst push, and Zentalis outlined a dual development path for its WEE1 inhibitor azenosertib. Oruka Therapeutics emphasized an annual dosing strategy for its dermatology pipeline, while Rapport Therapeutics presented from a cash-rich position. ORIC Pharmaceuticals flagged pipeline bets alongside trial delays, and Immunic flagged upcoming multiple sclerosis data as a near-term event. Oculis described a strategic shift toward neuroprotection in ophthalmology.

On the commercial and medtech side, Kestra Medical reported rising growth and margins, MaxCyte said its Akron deal lifted its outlook, and Evolus highlighted growth alongside pipeline development. Claritev and TriSalus presented at the Canaccord Medtech Forum, with Claritev describing expansion beyond its payer base and TriSalus signaling a near-term reset ahead of longer-term growth. BioMarin addressed growth, deal activity, and pipeline rebuilding efforts at Stifel, and BillionToOne described broadening commercial growth. Castle Biosciences announced a forthcoming presentation at the Piper Sandler 38th Annual Healthcare Conference. Alto Neuroscience was separately flagged by Jefferies as facing a pivotal 2027, with analysts identifying three clinical catalysts to watch.